Myeloproliferative Neoplasms

The FDA has granted priority review to a new drug application for pacritinib as a potential treatment option for patients with myelofibrosis and severe thrombocytopenia, defined as platelet counts less than 50 x 109/L.

Abdulraheem Yacoub, MD, discusses the rationale for combining PI3K inhibitors with ruxolitinib in myelofibrosis, the results of the phase 2 study with parsaclisib, and ongoing phase 3 trials evaluating this novel combination.

Srdan Verstovsek, MD, PhD, discusses the rationale for utilizing ruxolitinib and navitoclax in patients with relapsed/refractory myelofibrosis.

The biologics license application seeking the approval of ropeginterferon alfa-2b-njft for use in the treatment of patients with polycythemia vera has been resubmitted to the FDA.

Srdan Verstovsek, MD, PhD, discusses future research efforts for patients with myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Unmet needs and current areas that are being studied in in essential thrombocythemia.

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea. 

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

Abdulraheem Yacoub, MD, discusses the rationale behind examining parsaclisib following suboptimal response to ruxolitinib in patients with myelofibrosis.

Now that interferon-alpha has been shown to prolong survival in patients with polycythemia vera, it is important that investigative efforts focus on developing a better understanding on the biology of the disease and the mechanisms by which the agent actually improves outcomes.

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

Ghaith Abu-Zeinah, MD, shares what inspired the study examining IFN vs standard strategies, key findings from the research, and the clinical implications of these data on the PV treatment paradigm.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

The combination of navitoclax and ruxolitinib simultaneously inhibits 2 key mechanisms that promote myelofibrosis, resulting in an improvement in symptom control and positive changes in response biomarkers in patients with high-risk disease.

The rolling submission of a new drug application has been completed and submitted to the FDA to support the approval of pacritinib as a treatment for patients with myelofibrosis and severe thrombocytopenia defined as having platelet counts less than 50 x 109/L.

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice. 

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic. 

What to look forward to in the polycythemia vera space, including new clinical trials.